{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":48,"n_cols":5,"rows_kept":48,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[18,2,18,3],[19,2,19,3],[23,2,23,3],[26,2,26,3],[26,4,26,5],[27,2,27,3],[27,4,27,5],[28,2,28,3],[29,2,29,3],[33,2,33,3],[34,2,34,3],[35,2,35,3],[36,2,36,3],[38,2,38,3],[41,2,41,3],[42,2,42,3],[46,2,46,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910450176503321"]
[null,null,"Autore",null,"Deyo Richard A"]
[null,null,"Titolo",null,"Hope or hype [[electronic resource] ] : the obsession with medical advances and the high cost of false promises / / Richard A. Deyo, Donald L. Patrick"]
[null,null,"Pubbl/distr/stampa",null,"New York, : AMACOM, American Management Association, c2005"]
[null,null,"ISBN",null,"1-281-12625-X"]
[{"$nulls":4},"9786611126254"]
[{"$nulls":4},"0-8144-2859-2"]
[null,null,"Descrizione fisica",null,"1 online resource (352 p.)"]
[null,null,"Disciplina",null,"610/.28"]
[null,null,"Soggetti",null,"Medical innovations - United States - Evaluation"]
[{"$nulls":4},"Medical technology - United States - Evaluation"]
[{"$nulls":4},"Medical care - Technological innovations - United States - Evaluation"]
[{"$nulls":4},"Medical care - United States - Evaluation"]
[{"$nulls":4},"Medical innovations - Economic aspects - United States"]
[{"$nulls":4},"Medical technology - United States - Cost effectiveness"]
[{"$nulls":4},"Medical care - Technological innovations - United States - Cost effectiveness"]
[{"$nulls":4},"Medical care, Cost of - United States"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Bibliographic Level Mode of Issuance: Monograph"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references (p. [291]-326) and index."]
[null,null,"Nota di contenuto",null,"Can there be too much of a good thing? the hazards of uncritically embracing medical advances -- What's the problem? don't we need lifesaving new treatments? -- Medical innovations and American culture: the call of the sirens -- Why more isn't always better: red herrings, side effects, and superbugs -- Why newer isn't always better: unpleasant surprises, recalls, and learning curves -- Social hazards: what we lose by uncritical use of new treatments -- How things really work: opinion makers and regulators of medical  advances -- What will you swallow? how drug companies get you to buy more expensive drugs than you may need -- Making friends, playing monopoly, and dirty tricks: other industry strategies -- Stacking the deck? how to get the \"right\" answer in clinical research -- \"Cancer cured--film at 11:00\": the media's role in disseminating medical advances -- Doctors and "]
[{"$nulls":4},"hospitals: fueling the drive for new and more -- Advocacy groups: Mother Teresa's waiting room -- Holes in the safety net: the FDA and the FTC -- Ineffective. inferior or needlessly costly new drugs -- Medical devices that disappoint -- Ineffective or needlessly extensive surgery -- Weight loss technology: shedding pounds from your waistline or your wallet? -- For doctors: evidence-based medicine -- For insurers and researchers: pay now or pay more later -- For all decision makers: getting value for money -- For government: regulatory approaches to improve the dissemination of medical innovations -- For consumers: shared decision making."]
[{"$nulls":4},"Can there be too much of a good thing? the hazards of uncritically embracing medical advances -- What's the problem? don't we need lifesaving new treatments? -- Medical innovations and American culture: the call of the sirens -- Why more isn't always better: red herrings, side effects, and superbugs -- Why newer isn't always better: unpleasant surprises, recalls, and learning curves -- Social hazards: what we lose by uncritical use of new treatments -- How things really work: opinion makers and regulators of medical  advances -- What will you swallow? how drug companies get you to buy more expensive drugs than you may need -- Making friends, playing monopoly, and dirty tricks: other industry strategies -- Stacking the deck? how to get the \"right\" answer in clinical research -- \"Cancer cured--film at 11:00\": the media's role in disseminating medical advances -- Doctors and hospitals: fueling the drive for new and more -- Advocacy groups: Mother Teresa's waiting room -- Holes in the safety net: the FDA and the FTC -- Useless, harmful, or marginal: popular treatments that caused unnecessary disability, dollar costs, or death -- Ineffective or inferior new drugs -- Medical devices that disappoint -- Ineffective or needlessly extensive surgery -- Weight loss technology: shedding pounds from your waistline or your wallet? -- Crossing the threshold: improving the transition from \"experimental\" to \"standard care\" -- For doctors: evidence-based medicine -- For insurers and researchers: pay now or pay more later -- For all decision makers: getting value for money -- For government: regulatory approaches to improve the dissemination of medical innovations -- For consumers: shared decision making."]
[null,"2.","Record Nr.",null,"UNINA9910144013303321"]
[null,null,"Titolo",null,"Advances in enzymology and related areas of molecular biology . Volume 54 [[electronic resource] /] / edited by Alton Meister"]
[null,null,"Pubbl/distr/stampa",null,"New York, : Wiley, 1983"]
[null,null,"ISBN",null,"1-282-30107-1"]
[{"$nulls":4},"9786612301070"]
[{"$nulls":4},"0-470-12299-4"]
[{"$nulls":4},"0-470-12372-9"]
[null,null,"Edizione",null,"[11th ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (522 p.)"]
[null,null,"Collana",null,"Advances in enzymology and related areas of molecular biology ; ; 54"]
[null,null,"Disciplina",null,"572"]
[{"$nulls":4},"612.0151"]
[null,null,"Soggetti",null,"Clinical enzymology"]
[{"$nulls":4},"Enzymes"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"ADVANCES IN ENZYMOLOGY AND RELATED AREAS OFMOLECULAR BIOLOGY; CONTENTS; Mechanism and Basis for Specificity of TransglutaminaseCatalyzed e-(y-Glutamyl) Lysine Bond Formation; Fluorinated Pyrimidines and Their Nucleosides; Regulation of Fructose Bisphosphatase Activity; Methylthioadenosine; Cardiac Cytochrome c1; Creatine Kinase: Structure-Activity Relationships; Author Index; Subject Index; Cumulative Index. Vols. 1-54"]
[null,null,null,"Sommario/riassunto","Mechanism and Basis for Specificity of Transglutaminase-Catalyzed &epsis;(?-Glutamyl) Lysine Bond Formation (J. Folk). Fluorinated Pyrimidines and Their Nucleosides (C. Heidelberger, et al.). Regulation of Fructose Bisphosphatase Activity (G. Tejwani). Methylthioadenosine (F. Schlenk). Cardiac Cytochrome c 1 (T. King). Creating Kinase: Structure-Activity Relationships (G. Kenyon and G. Reed). Author and Subject Indexes. Cumulative Index."]